Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability

H Williams; R Clarke; N Bouras; J Martin; G Holt

doi:10.1046/j.1365-2788.2000.00284.x

Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability

H Williams, R Clarke, N Bouras, J Martin, G Holt

King's College London

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

The present study was designed to monitor the use of atypical antipsychotics in adults with intellectual disability and to evaluate the clinical effectiveness of these drugs. Twenty-one patients were commenced on an atypical antipsychotic: 12 on Olanzapine and nine on Risperidone. The ICD-10 diagnoses of the subjects were mild (13 cases) or moderate (8 cases) mental retardation, and psychiatric disorders (17 cases) with significant impairment of behaviour in 10 cases. Tolerability was good for 15 patients experiencing minimum or no side-effects, and medication was only stopped as a result: of side-effects in one case. Clinical global outcome was rated as minimally improved or better for 16 cases. The present findings suggest that the atypical antipsychotics Olanzapine and Risperidone are well tolerated by patients with intellectual disability and psychiatric disorders, and are broadly effective against target symptoms.

Original language	English
Pages (from-to)	164 - 169
Number of pages	6
Journal	Journal of Intellectual Disability Research
Volume	44
Issue number	2
DOIs	https://doi.org/10.1046/j.1365-2788.2000.00284.x
Publication status	Published - Apr 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1365-2788.2000.00284.x

Cite this

@article{b27cf671e1244d7c82345c26f1a63c54,

title = "Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability",

abstract = "The present study was designed to monitor the use of atypical antipsychotics in adults with intellectual disability and to evaluate the clinical effectiveness of these drugs. Twenty-one patients were commenced on an atypical antipsychotic: 12 on Olanzapine and nine on Risperidone. The ICD-10 diagnoses of the subjects were mild (13 cases) or moderate (8 cases) mental retardation, and psychiatric disorders (17 cases) with significant impairment of behaviour in 10 cases. Tolerability was good for 15 patients experiencing minimum or no side-effects, and medication was only stopped as a result: of side-effects in one case. Clinical global outcome was rated as minimally improved or better for 16 cases. The present findings suggest that the atypical antipsychotics Olanzapine and Risperidone are well tolerated by patients with intellectual disability and psychiatric disorders, and are broadly effective against target symptoms.",

author = "H Williams and R Clarke and N Bouras and J Martin and G Holt",

year = "2000",

month = apr,

doi = "10.1046/j.1365-2788.2000.00284.x",

language = "English",

volume = "44",

pages = "164 -- 169",

journal = "Journal of Intellectual Disability Research",

publisher = "WILEY-BLACKWELL",

number = "2",

}

TY - JOUR

T1 - Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability

AU - Williams, H

AU - Clarke, R

AU - Bouras, N

AU - Martin, J

AU - Holt, G

PY - 2000/4

Y1 - 2000/4

N2 - The present study was designed to monitor the use of atypical antipsychotics in adults with intellectual disability and to evaluate the clinical effectiveness of these drugs. Twenty-one patients were commenced on an atypical antipsychotic: 12 on Olanzapine and nine on Risperidone. The ICD-10 diagnoses of the subjects were mild (13 cases) or moderate (8 cases) mental retardation, and psychiatric disorders (17 cases) with significant impairment of behaviour in 10 cases. Tolerability was good for 15 patients experiencing minimum or no side-effects, and medication was only stopped as a result: of side-effects in one case. Clinical global outcome was rated as minimally improved or better for 16 cases. The present findings suggest that the atypical antipsychotics Olanzapine and Risperidone are well tolerated by patients with intellectual disability and psychiatric disorders, and are broadly effective against target symptoms.

AB - The present study was designed to monitor the use of atypical antipsychotics in adults with intellectual disability and to evaluate the clinical effectiveness of these drugs. Twenty-one patients were commenced on an atypical antipsychotic: 12 on Olanzapine and nine on Risperidone. The ICD-10 diagnoses of the subjects were mild (13 cases) or moderate (8 cases) mental retardation, and psychiatric disorders (17 cases) with significant impairment of behaviour in 10 cases. Tolerability was good for 15 patients experiencing minimum or no side-effects, and medication was only stopped as a result: of side-effects in one case. Clinical global outcome was rated as minimally improved or better for 16 cases. The present findings suggest that the atypical antipsychotics Olanzapine and Risperidone are well tolerated by patients with intellectual disability and psychiatric disorders, and are broadly effective against target symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0034042859&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2788.2000.00284.x

DO - 10.1046/j.1365-2788.2000.00284.x

M3 - Article

VL - 44

SP - 164

EP - 169

JO - Journal of Intellectual Disability Research

JF - Journal of Intellectual Disability Research

IS - 2

ER -

Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this